Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BlossomHill Therapeutics, Inc. (BLSM)

BlossomHill Therapeutics completes $150.0 million IPO at $16.00 per share

Neutral Impact 4 of 5 financing Written later

BlossomHill Therapeutics, Inc. closed its initial public offering on August 10, 2026, selling 9,375,000 shares of common stock at $16.00 per share. The company also adopted an amended and restated certificate of incorporation and amended and restated bylaws in connection with the closing. The filing gives gross proceeds before underwriting discounts and offering expenses, which are not yet deducted.

Key points

  • IPO of 9,375,000 shares of common stock at $16.00 per share, closed August 10, 2026
  • Approximate aggregate gross proceeds of $150.0 million, before underwriting discounts, commissions and estimated offering expenses
  • Amended and restated certificate of incorporation filed with Delaware Secretary of State; restated bylaws adopted effective August 10, 2026
  • Restated bylaws were previously filed as Exhibit 3.4 to Form S-1 (File No. 333-297512) on July 17, 2026

The filing

CompanyBlossomHill Therapeutics, Inc. (BLSM)
Form8-K, current report
Filed with the SECAug 10, 2026, 4:01 PM ET
Accession number0001193125-26-342316

Items reported: 5.03 Bylaw / Charter Amendment8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.